Sarepta Therapeutics (SRPT) Other Accumulated Expenses (2010 - 2026)

Sarepta Therapeutics' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $10.4 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 3.6% year-over-year to $10.4 million; the TTM figure through Mar 2026 stood at $10.4 million (up 3.6% YoY), while the FY2025 annual figure was $7.0 million, down 48.3% from the prior year.
• Other Accumulated Expenses was $10.4 million for Q1 2026 at Sarepta Therapeutics, up from $7.0 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $26.2 million in Q3 2022 to a low of $4.4 million in Q1 2023.
• Historically, Other Accumulated Expenses has averaged $10.5 million across 5 years, with a median of $9.8 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses slumped 75.5% in 2023, then surged 123.81% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $5.3 million in 2022, then rose by 21.81% to $6.5 million in 2023, then jumped by 108.14% to $13.5 million in 2024, then slumped by 48.3% to $7.0 million in 2025, then surged by 49.02% to $10.4 million in 2026.
• The last three Other Accumulated Expenses figures came in at $10.4 million (Q1 2026), $7.0 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.